Calypte und die Zeit nach AIDS2004 in Bangkok

 

nach oben immer größer wird...  

 

@kade: hättest du ihm doch nur nie diese webseite angegeben... LOL  

 

 

 

 

Seit langem wieder hohe Umsätze.

Kade gut das du wieder dich meldest ; ) .

Die machen das so spannend die Jungs, das ich kaum abwarten kann auf die presentation...

Gruß

C.O  

Sieht ja ziemlich bescheiden aus mit Caly. Ich glaub, das wird mit denen wirklich nix mehr. Ich an eurer Stelle würde langsam die Kohle in trockene Tücher bringen.


Grüße, ZN  

Wovon gehst du denn aus ??

Deine behauptungen mußt du doch hinterlegen können,überzeuge uns doch davon,zumindest der versuch ist es doch Wert uns zu überzeugen..

Gruß

C.O  

der kerl mit dem "hammer" im gesicht.

vielleicht hören sie ja auf dich...grins  

du weisst doch, ist bei mir immer so'n Bauchgefühl und irgendwie sehe ich langsam hier keine guten Perspektiven mehr. Für mich ist das Thema Caly-Investm. jedenfalls erledigt.

Und ausserdem wollt Ihr doch gar nicht wirklllich überzeugt werden, stimmts. Ich wünsche euch jedenfalls fette Gewinne auch wenn ich -wie gesagt- daran nicht mehr glauben kann.

Grüße, ZN  

 

wie ich sehe, kämpfst du immer noch gegen Windmühlen, so 'ne Art modernerner Don Quichote, hahaha

Grüße, ZN  

für DICH ist das Thema Caly-Investm. jedenfalls erledigt,aber für viele fängt es erst an.

Vergiss nicht jede geplante Investition zahlt sich aus..

Gruß

C.O
 

so´ne art don quichote....hahahahahahah....nur, das die windmühlen langsam kleiner und weniger werden, bis auf ein paar unverbesserliche, aber die nimmt auch bald keiner mehr ernst.

...jede geplante investition zahlt sich aus....prust...du meinst: muß sich auszahlen, so ist zumindestens deine wunschvorstellung...wie bei den anderen auch, die bis oberkante unterlippe in dem dreck stecken...  

wer hier nicht Ernst genommen wird ist doch klar..

Wenn der 911 er da ist kannst du damit auch fahren versprochen..

Gruß

C.O
 

wenige nicht mehr. die mehrzahl erkennt, dass ihr verbohrten calys absolut auf dem holzweg in den schwarzen kohlenkeller seid.

selbst von micha höre ich nichts mehr. ich hätte ihn aber auch vom intellekt her so eingeschätzt, dass er es irgendwann einmal kapiert...auch andere haben sich gedanken gemacht. von zeit zu zeit bekomme ich gewisse boardmails, entweder hier oder bei W:O...wo sich gewisse leute dann einsichtig und geläutert zeigen...

broker, du wirst nach deinem untergang hier nur noch mit dem fiat 500 davon fahren...  

 

We  believe  that the BED  Incidence  test can also  provide  policy  makers and
program  managers  with  valuable  insights   regarding  the  success  of  their
prevention  programs  and a  scientific  approach  to both  human and  financial
resource  allocation.   Incidence  estimates  help  determine  the  efficacy  of
prevention   programs  from  both  a  disease  spread  and  financial   resource
perspective and evaluate areas  appropriate for alternative  therapeutic  media,
such as vaccine trials. We expect the demand for this product to grow throughout
2005  as  the  CDC   continues   to  conduct   worldwide   workshops   to  train
representatives   from  various  governmental  public  health  and  humanitarian
organizations to use the test.

  STATUS OF NEW PRODUCTS

     HIV-1/2 RAPID TESTS

Our primary focus is developing  and  commercializing  new test products for the
rapid  detection  of  antibodies  to HIV-1 and HIV Type 2, a second  type of HIV
("HIV-2") in blood,  oral fluid and urine  samples using a lateral flow dipstick
design (the "HIV-1/2 Rapid Tests"). We are currently  conducting clinical trials
of these products in the People's Republic of China ("China"),  Uganda and South
Africa and expect to conduct other trials during 2005.  Pending local regulatory
approval,  we expect to have the blood test commercially  available early in the
second quarter of 2005 and the non-blood tests  available  before the seond half
of this year.

The largest numbers of cases of HIV are found in sub-Saharan Africa and Asia. It
is predicted that the next wave of the epidemic may occur in China,  India,  and
in the countries of Northern Africa and Eastern Europe.  The  characteristics of
these  markets  make  adoption of our  laboratory-based  ELISA tests a difficult
challenge. In vast areas of Africa and Asia in particular,  the lack of properly
equipped  laboratories,   properly  trained  technologists,   or  even  reliable
electricity   and  water  make  the  logistics   associated   with   traditional
laboratory-based   testing   algorithms   slow,   impractical   and  unreliable.
Self-contained  rapid  tests that are easy to perform  even in remote  locations
seem to offer tremendous promise in these high-risk settings.

Furthermore,  one of the challenges faced by clinicians around the world is that
of getting  patients to return to the testing  clinic for their HIV test results
several days or weeks after their initial  counseling and testing  session.  The
CDC has  reported  that up to 30% of the people  who  attend HIV  clinics in the
United  States do not return for their  results,  and whether  this is caused by
fear or by the inconvenience of revisiting the clinic,  the result is the same -
lost opportunities to further counsel,  and if necessary,  treat the public. The
problem is no better in the developing world.

Unfortunately,  HIV  testing  in the  developing  world  often  requires  a more
comprehensive  solution than a reliable  point-of-care test,  however.  Cultural
taboos about  giving  blood,  the fear of painful  blood  collection,  the risks
associated with the re-use or accidents  involving needles and lancets,  and the
stigma of being seen at an HIV clinic are all factors that can limit the utility
and effectiveness of rapid HIV tests.

The ability to perform HIV testing  without the need for a blood sample has been
shown in the past to significantly  increase voluntary testing rates.  Moreover,
the elimination of needles and lancets from the testing  process  simultaneously
eliminates   the  risk  of  accidental   infection   through  needle  re-use  or
needle-stick accident.  This apparent need for rapid HIV antibody tests that can
be performed safely and painlessly on non-blood samples in virtually any setting
drove our  development of rapid HIV tests for urine and oral fluid  samples,  in
addition to the traditional blood/serum/plasma format.


                                      7


Page 9

 

MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

The following  information  should be read in conjunction  with the consolidated
financial  statements  and related notes that are provided under Part II, Item 7
of this  Annual  Report  on  Form  10-KSB.  The  information  contained  in this
management's  discussion  and  analysis of  financial  condition  and results of
operations  ("MD&A"),  other  than  historical  information,  contains  "forward
looking  statements"  within the  meaning of The Private  Securities  Litigation
Reform  Act of 1995  that are based on  management's  current  expectations  and
assumptions.  Actual future  results could differ  materially.  This MD&A should
also be read in conjunction with the sections entitled  "Additional Factors That
May Affect Future Results" and "Forward-Looking Statements."

OVERVIEW AND OUTLOOK

Our financial  objective is to achieve  profitable growth.  Management  believes
that by providing a combination  of test  products,  we will be able to increase
revenues. Our efforts in 2003 and 2004 have been primarily focused on developing
new test  products and  acquiring the  intellectual  property  needed to develop
those products. Our efforts in 2004 have included reducing operating expenses by
closing our Alameda,  California  manufacturing  facility and  consolidating the
production of our ELISA tests in our Rockville  manufacturing  facility. We have
increased our overall investment in research and development. These research and
development  expenditures  have  enabled us to introduce  new and enhanced  test
products. Subject obtaining adequate financing, we plan to continue to focus our
efforts in 2005 on improving our operating  and gross  margins,  commercializing
our products and expanding our product offerings.

Sales of our ELISA tests  totaled  approximately  $2.8  million in 2004 and $3.5
million in 2003. Sales to international  customers  accounted for  approximately
16% and 15% of our product sale revenues in 2004 and 2003, respectively.

     Guidance  Our focus for 2005 is on the  commercialization  of our  HIV-1/2
rapid test,  initially in a  dipstick-format  and produced in Thailand.  We have
begun clinical trials in Uganda and South Africa and expect to begin  additional
trials during 2005 in several other African  countries,  including South Africa.
While there are different  regulations and customs in each foreign  country,  we
have distribution  relationships in place in several countries that will be part
of these next trials and we believe that the regulatory process can generally be
completed  in a few months.  Therefore,  we expect to begin  African and perhaps
southeast  Asian sales in mid-2005.  We are unable to predict with any certainty
the magnitude of such sales in 2005.

We have also begun clinical trials in China and have received  initial  feedback
from the field  that  leads us to believe  that all three of our  HIV-1/2  rapid
tests,  blood,  oral  fluid and  urine,  plus our serum and urine  Western  Blot
supplemental  tests will meet the accuracy  standards that have been employed by
the Chinese  regulatory  authorities  in approving  other HIV rapid  tests.  The
statistical  report  assessing  firm  conclusions  from the  clinical  trials is
expected  to be issued in the  second  quarter  of 2005.  In  parallel  with the
regulatory  approval  process,  we have  continued to advance our  manufacturing
strategy. We expect to have production available to support a commercial product
launch in China  subsequent  to  regulatory  approval  during the second half of
2005. There are several large markets in China,  including a recently  announced
commitment  by the  Chinese  government  to offer  voluntary  HIV testing to its
entire 1.36  billion  population.  With  trained  non-professionals  and a safe,
non-invasive alternative fluid - oral fluid or urine - testing program employing
the products  currently  involved in the clinical trial, we expect strong demand
for our products.  Beijing Calypte, our joint venture with Marr, will manage the
Chinese rapid test product  launch.  We are unable to predict with any certainty
the magnitude of rapid test sales in China, if any, in 2005.

Additionally,  we believe that the Ani Platform  provides us with an alternative
product format with potential  applicability  in both the  professional  and OTC
markets  worldwide.  We do not,  however,  expect to generate any revenues  from
products utilizing the Ani Biotech technology in 2005.

In  addition  to  the  rapid  test,  we  believe  the  Incidence  Test  to  be a
complementary  product that can provide policy makers and program  managers with
valuable  insights  regarding  the success of their  prevention  programs  and a
scientific  approach  to  resource  allocation.  We expect  the  demand for this
product  to grow  throughout  2005 as the CDC  continues  to  conduct  worldwide
workshops to train  representatives  from various governmental public health and
humanitarian  organizations  to use the test.  At this  time,  we are  unable to
predict with any certainty the level of incidence test sales in 2005, but expect
them to begin modestly early in the year and expand at an increasing rate in the
second half of 2005.  Additionally,  we have begun the research on a blood-based
rapid HIV incidence  test for  diagnostic  and  surveillance  purposes under the
terms of a Cooperative Research and Development Agreement with the CDC. Based on
the developmental and regulatory  timetables we project for this product,  we do
not expect to realize any revenue from its sale in 2005.


                                      33


Page 35
 

dann:

As of March 29, 2005, 171,207,589 shares of the registrant's common stock,
$.03 par value, were outstanding.

Sales of our ELISA tests  totaled  approximately  $2.8  million in 2004 and $3.5
million in 2003. Sales to international  customers  accounted for  approximately
16% and 15% of our product sale revenues in 2004 and 2003, respectively.

The
statistical  report  assessing  firm  conclusions  from the  clinical  trials is
expected  to be issued in the  second  quarter  of 2005.  


In  parallel  with the
regulatory  approval  process,  we have  continued to advance our  manufacturing
strategy. We expect to have production available to support a commercial product
launch in China  subsequent  to  regulatory  approval  during the second half of
2005.


Although we issued a
$2,000,000  Promissory Note (the "Promissory  Note") to Marr in January 2005, it
was due on  March  31,  2005 and the  proceeds  have  not  provided  us with the
liquidity to fully attain our business milestones and to achieve  profitability.
We have  negotiated  an extension of the maturity  date of the  Promissory  Note
until April 30, 2005.  


Our current cash  resources are not sufficient to sustain
our  operations  and achieve our  milestones  through the second quarter of 2005
without obtaining additional financing.  We believe that we will need to arrange
additional  financing  of  approximately  $15 million to sustain our  operations
throughout  2005,  including the funds required to repay the Promissory Note.

ELISA Test Sales  Sales of our urine  ELISA  Screening  and  Supplemental  Tests
accounted  for  55% and 67% of our  total  product  sales  for the  years  ended
December 31, 2004, and 2003, respectively.  We do not expect significant changes
in the level of sales or the  purchasers  of our current urine EIA screening and
supplemental tests in the near future.


Years Ended December 31, 2004 and 2003

Calypte's  revenues for 2004 totaled $3.3 million compared with $3.5 million for
2003,  a decrease  of $0.2  million or 5%.  Urine EIA  screening  test  revenues
decreased by $686,000 or 32% to $1,481,000  in 2004 compared with  $2,167,000 in
2003.  Urine Western Blot sales generally  follow a trend similar to that of the
screening test and decreased $85,000 or 55%, from $154,000 in 2003 to $69,000 in
2004.

International  sales of our EIA  screening  tests  accounted  for  approximately
$16,000 and $173,000 in 2004 and 2003,  respectively.  Our primary international
sales in 2003 were to our Chinese  distributor.  

Gross margin decreased from a loss of $2,654,000 (-77% of sales in 2003) to a
loss of $3,981,000 (-142% of sales in 2004) as a result of three primary
factors

Research and development  costs increased by $596,000 or 39%, from $1,544,000 in
2003 to $2,140,000 in 2004.


Selling,  general and administrative  costs decreased by $6,538,000 or 42%, from
$15,517,000  in 2003 to  $8,979,000  in  2004.




MUHAHAHAHAHA

das wichtigste im grossen und ganzen.

aber broker wird euch erklären, warum die zahlen trotzdem gut sind und wird seienn freund kade zu rate ziehen!!!

die zahlen sind so grottenschlecht, wie erwartet

ich sage nur: be aware of caly!!!!


 

jetzt wisst ihr wieder warum ich gegen caly bin. lest euch #4473 durch, da steht alles wichtige auf einen blick.

ich lasse euch jetzt wieder mit eurem scherbenhaufen alleine.

gute nacht!  

kaum auslandsverkäufe!!!

sinkende absatzzahlen!!!!

kaum mehr cash!!!

hohe kostenquote!!!

derbe verluste!!!

keine großaufträge!!!


darauf lege ich mich jetzt fest: es wird dieses jahr keine großaufträge mehr geben, wie ich euch schon sagte. jetzt träumt schön von eurer phantasie.

aber ihr wisst ja:

truth is stronger than fiction!!